Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07224308

Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mm

Sponsor: The Levine Center for Plastic Surgery

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the long-term safety and effectiveness of Ultherapy Prime (MFU-V) for improving lines, wrinkles, laxity, and crepiness of the lower face, submentum, and neck. The study will enroll adult male and female subjects aged 25-65 with moderate to severe lower-face and neck skin laxity who are appropriate candidates for non-invasive ultrasound treatment. The main questions this study aims to answer are: Does Ultherapy Prime delivered at multiple depths compared to a single-depth (1.5 mm) treatment improve clinical lifting, tightening, and smoothing of the lower face and neck over a 12-month period? Does treatment with Ultherapy Prime stimulate measurable improvements in collagen-related skin quality, patient satisfaction, and investigator-assessed aesthetic outcomes? Because the study includes two treatment approaches, researchers will compare a multi-depth MFU-V treatment protocol versus a single-depth (1.5 mm) MFU-V treatment protocol to determine whether multi-depth energy delivery provides superior or longer-lasting clinical improvement. What Participants Will Do Participants will: Attend a total of 5 study visits over 12 months (Screening/Treatment, 1-month, 3-month, 6-month, and 12-month follow-ups). Undergo a single Ultherapy Prime treatment session at either multiple depths or at the 1.5 mm depth only. Complete standardized photography, including 2D and 3D images, at all timepoints. Participate in clinical assessments, including GAIS scoring, cutometer elasticity measurements (if applicable), and investigator- and patient-reported satisfaction scales. Follow pre-visit requirements, including: No moisturizers, lotions, or topical products on the treatment area before each visit No hair in the treatment area (shave the day prior if needed) Complete questionnaires evaluating satisfaction, comfort, and perceived treatment benefits. Adhere to follow-up schedules, avoiding elective aesthetic procedures to the lower face, submentum, or neck during the study period.

Key Details

Gender

All

Age Range

25 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2025-10-24

Completion Date

2026-12-30

Last Updated

2025-11-04

Healthy Volunteers

Yes

Conditions

Laxity; Skin

Interventions

DEVICE

Ultherapy Prime

Ultherapy Prime is an FDA-cleared micro-focused ultrasound (MFU-V) device used for non-invasive lifting and tightening of the lower face, submentum, neck, brow, and improvement of décolleté lines. It delivers precise ultrasound energy at controlled depths to create thermal coagulation points that stimulate neocollagenesis, promoting new collagen and elastin for improved firmness and visible lifting. The system includes real-time DeepSEE® imaging to visualize tissue layers and ensure accurate energy placement. Ultherapy Prime uses transducers at FDA-cleared depths such as 1.5 mm, 2.0 mm, 3.0 mm, and 4.5 mm. For this study, treatment is delivered at multiple depths or only at 1.5 mm depending on randomization. It is non-surgical, non-ionizing, does not break the skin, and improvement develops gradually as collagen remodels.

Inclusion Criteria: * Male or female subjects between 25 and 65 years of age at the time of screening. Presence of moderate to severe laxity, fine lines, or crepiness of the lower face, submentum, and/or neck that is appropriate for improvement with non-invasive MFU-V treatment. Skin condition not advanced enough to require surgical correction. Willingness to refrain from elective aesthetic procedures involving the face, submentum, or neck for the entire 12-month duration of the study. Ability and willingness to comply with all study visits, procedures, and follow-up requirements. Sufficient English language proficiency to understand study instructions and complete questionnaires. For participants of childbearing potential: negative urine pregnancy test on the day of treatment and willingness to use adequate contraception during the study. Ability to provide written informed consent. Exclusion Criteria: * Male or female subjects between 25 and 65 years of age at the time of screening. Presence of moderate to severe laxity, fine lines, or crepiness of the lower face, submentum, and/or neck that is appropriate for improvement with non-invasive MFU-V treatment. Skin condition not advanced enough to require surgical correction. Willingness to refrain from elective aesthetic procedures involving the face, submentum, or neck for the entire 12-month duration of the study. Ability and willingness to comply with all study visits, procedures, and follow-up requirements. Sufficient English language proficiency to understand study instructions and complete questionnaires. For participants of childbearing potential: negative urine pregnancy test on the day of treatment and willingness to use adequate contraception during the study. Ability to provide written informed consent. Exclusion Criteria: Active systemic or local skin disease (e.g., eczema, psoriasis, dermatitis, infection) that may affect wound healing or the evaluation of results. Scarring, tattoos, or significant pigmentary alterations in the planned treatment areas. Metallic implants or other implanted electronic devices (e.g., pacemakers) in or near the treatment area. Open wounds, lesions, active herpes simplex, or active cystic/severe inflammatory acne in the treatment area. Use of isotretinoin or other oral retinoids within the past 12 months or planned use during the study. Microdermabrasion or medical-grade glycolic acid treatments to the treatment area within 2 weeks prior to participation. Deep dermal scarring, thick sebaceous skin, or severe solar elastosis in the treatment area that may interfere with treatment or evaluation. Intention to gain or lose ≥ 2 BMI units during the 12-month study period. Known allergy or hypersensitivity to any component of the device or ultrasound coupling gel. History of chronic drug or alcohol abuse or opioid dependence. Recent aesthetic procedures to the lower face, submentum, or neck that may confound study outcomes (e.g., fillers, neurotoxins, lasers, threads, RF, ultrasound) within the protocol-specified washout period. Participation in another clinical study involving an investigational device or drug within 30 days prior to treatment. Pregnancy, breastfeeding, or plans to become pregnant during the study. Any condition that, in the opinion of the investigator, would increase risk or interfere with study participation or data interpretation.

Locations (1)

The Levine Center for Plastic Surgery

New York, New York, United States